Ask AI

Search

Updates

Loading...

Home

New Question

pembrolizumab in colon cancer

Answer

Pembrolizumab, a monoclonal antibody that targets the programmed death-1 (PD-1) receptor, plays a significant role in the treatment of colon cancer, particularly in cases of microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) metastatic colorectal cancer (CRC).

First-line therapy for MSI-H/dMMR metastatic CRC

In conclusion, pembrolizumab plays a significant role in the treatment of MSI-H/dMMR metastatic CRC as a first-line therapy, offering a targeted approach for patients with these specific genetic markers.

References

1

Pembrolizumab

Dosages

Dosage

Treatment of cancer in adults (high tumor mutational burden)

Pathway